← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #453 OF 1,000 MOST-CITED

Written QA procedures established, followed

FDA cited this observation 42 times across 33 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs42
BY FISCAL YEAR
FY20269
FY202510
FY20242
FY20231
FY20221
FY20211
FY20201
FY20198
FY20188
FY20171

How FDA worded it — real examples

You did not follow written quality assurance procedures.

PETNET Solutions, Inc. · Denver, Colorado · Drugs · 2026-03-24

You did not establish and follow written quality assurance procedures.

Jubilant DraxImage Radiopharmacies · Mobile, Alabama · Drugs · 2026-03-23

You did not follow written quality assurance procedures.

PETNET Solutions, Inc. · Las Vegas, Nevada · Drugs · 2026-03-06

You did not establish written quality assurance procedures.

Biomedical Research Foundation of Northwest Louisiana · Shreveport, Louisiana · Drugs · 2026-02-20

You did not follow written quality assurance procedures.

The Methodist Hospital Research Institute · Houston, Texas · Drugs · 2026-02-13

You did not establish and follow written quality assurance procedures.

Cardinal Health 414 LLC · Tampa, Florida · Drugs · 2026-02-06

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharmaceutical quality systemPharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →